Clinical predictability is the key to reducing drug development costs. At the moment, the high failure rate of drugs entering clinical trials is costing the industry billions of dollars per year.

Massively parallel and redundant by design, the human system offers significant challenges to drug design efforts. Predicting clinical outcomes with any degree of accuracy is an absolutely daunting task. That is why Serometrix has spent years perfecting the ability to discover new and novel target and peptide ligand pairs that already function nearly flawlessly, and therefore quite predictably, in the human system.

Using the human system as a guide, Serometrix is focused on methodically "discovering" an entirely new class of lead compounds with predictable efficacy, predictable toxicity, and predictable side effects. These new starting points are then optimized for binding affinity using a host of modern molecular modeling techniques.

Optimum clinical predictability can only be obtained by understanding and emulating these highly evolved protein interaction segments, which have been derived from the very human system in which they are to clinically operate. It is upon this fundamental premise that Serometrix operates.